Ombipepimut-S

Summary

Ombipepimut-S (CHEMBL4297235) is a phase-3 clinical-stage unknown; indicated across 4 conditions including glioblastoma and acute myeloid leukemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 4 conditions
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297235
Name	Ombipepimut-S
Type	Unknown
Max phase	3

Also known as: DSP-7888, Ombipepimut-s, OMBIPEPIMUT-S

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
glioblastoma	3	MONDO:0018177	EFO:0000519
acute myeloid leukemia	2	MONDO:0018874	EFO:0000222
myelodysplastic syndrome	1	MONDO:0018881	EFO:0000198
diffuse intrinsic pontine glioma	1	MONDO:0006033	EFO:1000026

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE1/PHASE2	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02436252	PHASE1/PHASE2	COMPLETED	Study of DSP-7888 in Patients With Myelodysplastic Syndrome
NCT02750891	PHASE1/PHASE2	COMPLETED	A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas
NCT04747002	PHASE2	UNKNOWN	Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine Dainippon Sumitomo Phama(DSP)-7888 for Acute Myeloid Leukemia Patients.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).